Maintenance Therapy in Ovarian Cancer
Current Obstetrics and Gynecology Reports · 29.10.2026 · 15 (1)
DOI: 10.1007/s13669-026-00499-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Obstetrics and Gynecology Reports, online erschienen am 29.10.2026. Verfasst von Grace Chen und 1 weiteren Autor:innen. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Purpose of Review This report reviews foundational and recent literature on maintenance therapy in ovarian cancer, both in the frontline setting and in platinum-sensitive recurrence. Recent Findings Bevacizumab and PARP inhibitors have been well established as frontline maintenance for BRCA wild-type and BRCA mutated or homologous repair deficient disease, respectively. For platinum-sensitive recurrence, PARP inhibitors are reserved for BRCA mutated disease; Bevacizumab can be considered if used alongside chemotherapy in management of the recurrence. Summary Advanced epithelial ovarian cancer often responds well to initial chemotherapy and cytoreductive surgery, but rapid recurrence is common. Maintenance therapy with Bevacizumab or PARP inhibitors, in both frontline treatment and in platinum-sensitive recurrence, has improved progression-free survival. We review literature that informs recommendations for selection of maintenance regimens as well as recent findings narrowing some of their indications for use.
Zitieren
APA
Chen, G., & Chapman, J. (2026). Maintenance Therapy in Ovarian Cancer. Current Obstetrics and Gynecology Reports, 15(1). https://doi.org/10.1007/s13669-026-00499-5
Vancouver
Chen G, Chapman J. Maintenance Therapy in Ovarian Cancer. Current Obstetrics and Gynecology Reports. 2026;15(1). doi:10.1007/s13669-026-00499-5
BibTeX
@article{Chen2026,
author = {Chen, Grace and Chapman, Jocelyn},
title = {Maintenance Therapy in Ovarian Cancer},
journal = {Current Obstetrics and Gynecology Reports},
year = {2026},
volume = {15},
number = {1},
doi = {10.1007/s13669-026-00499-5}
}
EUVIMED